ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

GENE Genetic Technologies Ltd

2.32
0.00 (0.00%)
Pre Market
Last Updated: 03:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 2.15
Ask Price 2.55
News -
Share Name Share Symbol Market Stock Type
Genetic Technologies Ltd GENE NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 2.32 03:00:00
Open Price Low Price High Price Close Price Previous Close
2.32
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0  2.32 USD

Genetic Technologies Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.38B 11.54B - 10.35M -11.75M -0.00 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Genetic Technologies

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GENE Message Board. Create One! See More Posts on GENE Message Board See More Message Board Posts

GENE Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.

Your Recent History

Delayed Upgrade Clock